Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Fujisawa

Showing results (151-160 of 724) with videos related to

Pageof 73
Sort By:
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Urology|November 30, 2014
Objective assessment of residual nerve tissues in radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile functionHideaki Miyake, Hosny M Behnsawy, Nobuyuki Hinata, et al.
Urologic Oncology|January 26, 2015
Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladderMasatomo Nishikawa, Hideaki Miyake, Hosny M Behnsawy, et al.
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Anticancer Research|May 13, 2015
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell CarcinomaAkira Miyazaki, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|February 21, 2015
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinibHideaki Miyake, Ken-ichi Harada, Akira Miyazaki, et al.
Urologic Oncology|September 6, 2011
Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cellsHosny M Behnsawy, Hideaki Miyake, Yuji Kusuda, et al.
Medical Oncology (Northwood, London, England)|October 15, 2013
Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitorsMasafumi Kumano, Hideaki Miyake, Ken-ichi Harada, et al.
Current Urology|February 19, 2016
Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core BiopsyHiromoto Tei, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|May 6, 2014
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in JapanHideaki Miyake, Akira Miyazaki, Ken-Ichi Harada, et al.
Pageof 73

Showing results (151-160 of 724) with videos related to

Sort By:
Pageof 73
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Urology|November 30, 2014
Objective assessment of residual nerve tissues in radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile functionHideaki Miyake, Hosny M Behnsawy, Nobuyuki Hinata, et al.
Urologic Oncology|January 26, 2015
Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladderMasatomo Nishikawa, Hideaki Miyake, Hosny M Behnsawy, et al.
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Anticancer Research|May 13, 2015
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell CarcinomaAkira Miyazaki, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|February 21, 2015
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinibHideaki Miyake, Ken-ichi Harada, Akira Miyazaki, et al.
Urologic Oncology|September 6, 2011
Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cellsHosny M Behnsawy, Hideaki Miyake, Yuji Kusuda, et al.
Medical Oncology (Northwood, London, England)|October 15, 2013
Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitorsMasafumi Kumano, Hideaki Miyake, Ken-ichi Harada, et al.
Current Urology|February 19, 2016
Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core BiopsyHiromoto Tei, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|May 6, 2014
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in JapanHideaki Miyake, Akira Miyazaki, Ken-Ichi Harada, et al.
Pageof 73